Fig. 4: Cd73 inactivation in the non-hematopoietic compartment hinders tumor progression causing tumor regression.

a C57BL/6 WT and Cd73^null mice received 1 × 10⁶ EG7 tumors s.c. were monitored for tumor progression every other day. Representative images illustrate the tumor size in WT and Cd73^null mice at 15 days post-inoculation. b At 9 days post-EG7 inoculation, tumors were collected from WT and Cd73^null mice for analysis of EG7-CAF percentage and phenotype. c The percentage of tumor infiltrating CD8⁺ T cells and IFN-γ⁺ effectors in the EG7 TME of WT and Cd73^null mice were analyzed, summarized, and shown to the right. d Schematic diagram shows reciprocal BMT strategy between WT C57BL/6 (GFP-Tg) and Cd73^null mice. e Two months post-BMT, EG7 tumors were established s.c. in these BMT mice and tumor progression was examined every other day. f Representative FACS plots (left) and summary (right) of tumor-infiltrating CD8⁺ T cells in the BMT mice are presented. g The representative histograms show CD73 expression (red line) compared with isotype control (gray) in CAFs and T cells of the BMT mice. h EG7-CAFs from WT and Cd73^null mice were purified via FACSort. Their capacity and kinetics for ADO conversion from 200 μM AMP was determined. i The capacity of WT and Cd73^null CAF-conditioned medium in the absence (CAF-CM) or presence of 200 μM AMP (AMP-CAF-CM) for inhibiting T cell proliferation as CFSE dilution was examined. Data depict mean ± SEM. Student’s t-test. n = 5. Source data are provided in the Source Data file.